Analysts await Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.52 EPS, down 38.46% or $0.2 from last year’s $-0.32 per share.

At the moment 5 analysts are watching Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), 2 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 4 analysts have a mean sales target of 0.00 million. For the quarter ending Sep-16, 4 analysts have a mean sales target of 0.00 million whilst for the year ending Dec-16, 4 analysts have a mean target of 0.00 million.

In terms of earnings per share, 4 analysts have a -0.46 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 4 analysts have a -0.49 EPS mean target and for the quarter ending Sep-16 there are 5 estimates of -1.22 EPS.

The biggest institutional shareholders in Aldeyra Therapeutics, Inc. include Domain Associates, LLC which owns 2 million shares in the company valued at $20.29 million. Johnson & Johnson is the second biggest holder with 2 million shares currently valued at 17.82 million whilst Fidelity Management and Research Company has 1 million shares valued at 9.75 million.

Total shares held by institutions as of the most recent company filings are 8,111,015 with a reported 614,070 bought and 775,471 sold. These holdings make up 83.52% of the company’s outstanding shares.

Currently insiders hold 72,214 shares in the business which makes up 0.74% of shares. The biggest holder currently is Dr. Todd C. Brady, M.D. who owns 42,185 shares (0.43% of those outstanding), whilst C. Boyd Clarke holds 15,500 (0.16% of shares outstanding) and Martin J. Joyce holds 13,500 (0.14% of shares outstanding).

The stock decreased 1.90% or $0.12 during the last trading session.